AGS 62P1

Drug Profile

AGS 62P1

Alternative Names: AGS62P1

Latest Information Update: 16 Aug 2016

Price : $50

At a glance

  • Originator Agensys
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Leukaemia

Most Recent Events

  • 09 Aug 2016 Agensys and Astellas Pharma plan a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater, Monotherapy) in USA and Canada (IV) (NCT02864290)
  • 16 Apr 2016 Preclinical trials in Leukaemia in USA (Parenteral) prior to April 2016
  • 16 Apr 2016 Pharmacodynamics data from preclinical trials in Leukaemia presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top